Neurogene Reveals Proposed Public Offering; No Size Disclosed
Neurogene Inc. (NASDAQ: NGNE ), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose